文献速递前列腺癌

前列腺mpMRI质量对前列腺癌诊断准确性的前瞻性影响

Impact of prostate mpMRI quality on diagnostic accuracy in prostate cancer: a prospective study.
PubMed 文献 · BJU Int · 2026-07-08

该前瞻性研究纳入246例在外院行mpMRI后转诊至三级中心行前列腺活检的患者,用PI-QUAL v2和PI-RADS v2.1集中复审图像。PI-QUAL 3扫描对临床显著前列腺癌的诊断准确性高于PI-QUAL 1-2(AUC 0.79 vs 0.66,P=0.01),集中复审使近半数PI-RADS评估被重新分类。

要点

  • 高质量mpMRI(PI-QUAL 3)对csPCa诊断准确性约提高15%。
  • PI-QUAL 3扫描中不确定PI-RADS 3比例更低(8% vs 27%)。
  • 集中专家复审可重新分类近半数PI-RADS评估并提高检出准确性。

核心结论

  • 高质量mpMRI对csPCa的诊断准确性约提高15%,且不确定发现比例更低。
  • 集中专家复审重新分类了近半数PI-RADS评估,支持 upfront 高质量采集与PI-QUAL质控。

研究设计与样本

  • 前瞻性研究,2024年6月至2025年7月连续纳入246例外院mpMRI后转诊行前列腺活检的患者。
  • 所有患者行系统活检,有指征时加靶向活检;外院mpMRI由不知临床病理数据的专家泌尿放射科医生集中复审。
  • 使用PI-QUAL v2和PI-RADS v2.1重新评估图像质量与病灶分级,按PI-QUAL 1-2 vs 3分层比较AUC。

主要发现

  • 中位年龄66.5岁(IQR 61-73),中位PSA 6.6 ng/mL(IQR 4.8-9.7),检出csPCa 128例(52%)。
  • 复审后PI-QUAL 1、2、3分别有49例(20%)、113例(46%)、84例(34%)。
  • 不确定PI-RADS 3比例在PI-QUAL 1为27%、PI-QUAL 2为15%、PI-QUAL 3为8%。
  • PI-QUAL 3扫描诊断准确性高于PI-QUAL 1-2(AUC 0.79 vs 0.66,P=0.01)。
  • 集中复审提高csPCa检出:PI-QUAL 1-2的AUC从0.63升至0.78(P<0.01),PI-QUAL 3从0.77升至0.89(P<0.01)。

关键数值与推荐

  • csPCa定义为ISUP分级≥2。
  • 图像质量按PI-QUAL v2评分,病灶按PI-RADS v2.1评分。
  • 准确性用ROC曲线下面积AUC评估,按PI-QUAL 1-2 vs 3分层。

临床怎么用

  • 应优先保证mpMRI的 upfront 高质量采集,并以PI-QUAL进行质控。
  • 对低质量外院mpMRI应考虑集中专家复审,以减少不确定发现并优化活检决策。
  • 高质量mpMRI有助于减少不必要的前列腺穿刺操作。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To prospectively evaluate the influence of multiparametric magnetic resonance imaging (mpMRI) quality, as assessed by the Prostate Imaging Quality (PI-QUAL) score, on diagnostic accuracy in men undergoing prostate biopsy after external mpMRI at a tertiary referral center. MATERIALS AND METHODS: From June 2024 to July 2025, a total of 246 consecutive patients referred for prostate biopsy after external mpMRI were prospectively enrolled. All patients underwent systematic biopsy with targeted biopsy when indicated. External mpMRI scans were centrally reviewed by expert uro-radiologists blinded to clinical and pathological data. Image quality and lesion grading were reassessed using PI-QUAL v2 and Prostate Imaging Reporting and Data System (PI-RADS) v2.1. Accuracy for clinically significant prostate cancer (csPCa; International Society of Urological Pathology [ISUP] grade ≥2) was assessed using receiver operating characteristic-derived area under the curve AUC before and after review, stratified by PI-QUAL (1-2 vs 3). RESULTS: Median age and prostate-specific antigen (PSA) were 66.5 years (interquartile range [IQR] 61-73) and 6.6 ng/mL (IQR 4.8-9.7), respectively, and csPCa was detected in 128 patients (52%). After review, 49 (20%), 113 (46%), and 84 (34%) mpMRI scans were classified as PI-QUAL 1, 2, and 3, respectively. The proportion of indeterminate PI-RADS 3 findings was 27% for PI-QUAL 1, 15% for PI-QUAL 2, and 8% for PI-QUAL 3. PI-QUAL 3 scans demonstrated greater diagnostic accuracy than PI-QUAL 1-2 (AUC 0.79 vs 0.66, P = 0.01). Central review improved csPCa detection in both PI-QUAL 1-2 (AUC 0.63 vs 0.78, P < 0.01) and PI-QUAL 3 (AUC 0.77 vs 0.89, P < 0.01) scans. CONCLUSIONS: High-quality mpMRI achieved approximately 15% higher diagnostic accuracy for csPCa and were associated with a lower prevalence of indeterminate findings than were low-quality MRI scans; centralized expert review reclassified nearly half of PI-RADS assessments. These findings support upfront high-quality mpMRI acquisition and PI-QUAL-based quality control to optimize diagnosis and reduce unnecessary procedures.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Cannoletta D, Brembilla G, Longoni M, et al. Impact of prostate mpMRI quality on diagnostic accuracy in prostate cancer: a prospective study. BJU Int. 2026. PMID: 42417115. doi:10.1111/bju.70373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。